CY1105878T1 - Βελτιωμενο συστημα διαδepμικης χορηγησης - Google Patents

Βελτιωμενο συστημα διαδepμικης χορηγησης

Info

Publication number
CY1105878T1
CY1105878T1 CY20061101845T CY061101845T CY1105878T1 CY 1105878 T1 CY1105878 T1 CY 1105878T1 CY 20061101845 T CY20061101845 T CY 20061101845T CY 061101845 T CY061101845 T CY 061101845T CY 1105878 T1 CY1105878 T1 CY 1105878T1
Authority
CY
Cyprus
Prior art keywords
amino
drug
matrix
functional drug
tds
Prior art date
Application number
CY20061101845T
Other languages
Greek (el)
English (en)
Inventor
Mike Hannay
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Original Assignee
Schwarz Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma Ag filed Critical Schwarz Pharma Ag
Publication of CY1105878T1 publication Critical patent/CY1105878T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20061101845T 2002-07-30 2006-12-21 Βελτιωμενο συστημα διαδepμικης χορηγησης CY1105878T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02016864A EP1386604A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system
EP03766330A EP1524971B1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system
PCT/EP2003/008319 WO2004012719A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system

Publications (1)

Publication Number Publication Date
CY1105878T1 true CY1105878T1 (el) 2011-02-02

Family

ID=30011092

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101845T CY1105878T1 (el) 2002-07-30 2006-12-21 Βελτιωμενο συστημα διαδepμικης χορηγησης

Country Status (21)

Country Link
EP (2) EP1386604A1 (cg-RX-API-DMAC7.html)
JP (1) JP4837915B2 (cg-RX-API-DMAC7.html)
KR (1) KR101016914B1 (cg-RX-API-DMAC7.html)
CN (1) CN100558350C (cg-RX-API-DMAC7.html)
AT (1) ATE343380T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003266252B2 (cg-RX-API-DMAC7.html)
BR (1) BR0313092A (cg-RX-API-DMAC7.html)
CA (1) CA2490573C (cg-RX-API-DMAC7.html)
CY (1) CY1105878T1 (cg-RX-API-DMAC7.html)
DE (1) DE60309329T2 (cg-RX-API-DMAC7.html)
DK (1) DK1524971T3 (cg-RX-API-DMAC7.html)
ES (1) ES2273042T3 (cg-RX-API-DMAC7.html)
IL (1) IL165917A (cg-RX-API-DMAC7.html)
MX (1) MXPA05000349A (cg-RX-API-DMAC7.html)
NO (1) NO334187B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ537476A (cg-RX-API-DMAC7.html)
PL (1) PL376999A1 (cg-RX-API-DMAC7.html)
PT (1) PT1524971E (cg-RX-API-DMAC7.html)
SI (1) SI1524971T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004012719A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200500255B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
ES2661767T3 (es) 2008-02-27 2018-04-03 Hisamitsu Pharmaceutical Co., Inc. Parche adhesivo para la piel y producto envasado
JP5537412B2 (ja) 2008-02-27 2014-07-02 久光製薬株式会社 貼付製剤
WO2011076879A1 (en) * 2009-12-22 2011-06-30 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
IT1311696B1 (it) * 1999-06-22 2002-03-19 Zanussi Elettromecc Compressore del fluido frigorigeno azionato da un motore elettricoa frequenza di alimentazione variabile
JP2002045699A (ja) * 2000-08-08 2002-02-12 Mitsubishi Electric Corp 排ガス浄化用層状電気化学触媒
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
CA2441064A1 (en) * 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
KR100904158B1 (ko) * 2001-03-16 2009-06-23 알자 코포레이션 펜타닐 투여용 경피성 패치
PT1256340E (pt) * 2001-05-08 2003-12-31 Sanol Arznei Schwarz Gmbh Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Also Published As

Publication number Publication date
PT1524971E (pt) 2007-01-31
AU2003266252A1 (en) 2004-02-23
EP1524971A1 (en) 2005-04-27
NO334187B1 (no) 2014-01-13
IL165917A (en) 2007-07-24
HK1083458A1 (zh) 2006-07-07
PL376999A1 (pl) 2006-01-23
DE60309329T2 (de) 2008-04-17
CA2490573A1 (en) 2004-02-12
NO20050770L (no) 2005-02-11
AU2003266252B2 (en) 2008-11-20
KR101016914B1 (ko) 2011-02-22
CA2490573C (en) 2011-06-07
WO2004012719A1 (en) 2004-02-12
EP1386604A1 (en) 2004-02-04
MXPA05000349A (es) 2005-03-31
IL165917A0 (en) 2006-01-15
ZA200500255B (en) 2006-01-25
ES2273042T3 (es) 2007-05-01
JP2005535686A (ja) 2005-11-24
NZ537476A (en) 2007-08-31
EP1524971B1 (en) 2006-10-25
JP4837915B2 (ja) 2011-12-14
CN100558350C (zh) 2009-11-11
SI1524971T1 (sl) 2007-02-28
ATE343380T1 (de) 2006-11-15
CN1671365A (zh) 2005-09-21
DE60309329D1 (de) 2006-12-07
BR0313092A (pt) 2005-06-21
DK1524971T3 (da) 2007-02-19
KR20050025638A (ko) 2005-03-14

Similar Documents

Publication Publication Date Title
DK1524975T3 (da) Forbedret, transdermalt tilförselssystem til indgivelse af rotigotin
CY1120228T1 (el) Διαδερμικο θεραπευτικο συστημα με μια επικολλουμενη στρωση, μεθοδος για την σιλικονοποιηση μιας οπισθιας στρωσης του συστηματος και χρηση της οπισθιας στρωσης
CY1108250T1 (el) Διαδερμικο θεραπευτικο συστημα για τη χορηγηση μη στεροειδικων αντιφλογιστικων που φερουν καρβοξυλομαδες, καθως και μεθοδος για την παραγωγη του
CY1106744T1 (el) Θεραπευτικο αυτοκολλητο διαδερμικο συστημα με φορεα πολυσιλοξανης που περιλαμβανει καψαϊκινη
AR048887A1 (es) Aparato y metodo de liberacion transdermica de agentes a base de hormona paratiroidea
CY1106811T1 (el) Διαδερμικη γρανισετρονη
AR097045A2 (es) Sistema terapéutico transdérmico
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
ATE526038T1 (de) Implantierbares medizinprodukt mit kontinuierlichem mittel-konzentrationsgefälle
CY1116638T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
DK1009393T3 (da) Transdermalt, terapeutisk system med hæfteklæbende reservoirlag og bagsidelag, som er elastisk i én retning
ATE343380T1 (de) Verbessertes transdermales abgabesystem
MX382132B (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno
DE502004006613D1 (de) Vorrichtung zur transdermalen Verabreichung von Wirkstoffen
DK0474647T3 (da) Fremgangsmåde og indretning til frigivelse af lægemidler til huden
DK1706133T3 (da) Fremgangsmåder til beskyttelse mod stråling ved anvendelse af flagellin
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
DK0379933T3 (da) Superficielt behandlingssystem med indhold af et antineoplastisk aktivstof, især 5-fluoruracil
MX2022006618A (es) Dispositivos medicos para generar calor y metodos de tratamiento que usan los mismos.
DE60315280D1 (de) Transdermale pflaster mit einer adhäsiven siliconmatrix stabilisiert mit methacryl copolymeren
TW200626196A (en) Microprojection array with improved skin adhesion and compliance
MXPA06001265A (es) Metodo y dispositivo para mejorar a permeabilidad de la piel humana.
ATE485817T1 (de) Pflaster, enthaltend fentanylum